Blink Eye Clinic: October update October 2018 — Newsletter:— Blink in Canberra Times... Blink Eye Clinic has recently featured in the Canberra Times and I've attached the articles below should you wish to read. I hope you enjoy and thank you very much for your time and support. Dr. Richard Barry Principal Surgeon at Blink October 2018 — Case of the Month:Subliminal to perceptable...— History
— Examination
— Imaging Spectralis MulticolourRight multicolor photograph at presentation showing area of apparent retinal thickening involving the right macula. Structural OCTPresenting OCT showing subfoveal fluid, thick and fibrinous under the photoreceptors, suggesting relative chronicity. Diagnosis of CSCR made. No risk factors on history. Structural OCTOCT 2 months later. Subtle improvement. No change in vision. Structural OCTPersistent subretinal fluid 6 months after initial presentation. Structural OCT12 months after presentation. Vision unchanged. Patient now interested in treatment. Subliminal laser [micropulse laser] performed. Structural OCT6 weeks after subliminal laser treatment. Significant improvement in central macular thickness after 12 months of persistent chronic subretinal fluid. Vision unchanged so far. — DiagnosisCentral Serous Chorioretinopathy:
— DiscussionSubliminal laser [micro-pulse laser] has shown significant promise in the treatment of multiple retinal conditions. In particular, central serous chorioretinopathy (CSCR), diabetic maculopathy and other retinal vascular diseases have shown statistically significant clinical responses to this laser treatment. In comparison to continuous wavelength laser, subliminal laser uses short pulses of laser energy, minimizing the accumulation of heat in the retina and therefore thermal damage. Subthreshold laser in general is replacing older, conventional, continuous wavelength laser for the treatment of extrafoveal clinically significant diabetic maculopathy. Subliminal laser, a form of subthreshold laser, can be used safely in extreme proximity to the fovea. This is very useful in CSCR and also in centre-involving diabetic maculopathy where anti-VEGF injections cannot be used (e.g. patient choice, financial restrictions etc.) or have proven limited in regards to response. Treatment is quick and completely painless and a useful addition to the armamentarium for the management of these retinal conditions. This particular case demonstrated the rapid response often seen in cases of chronic central serous retinopathy. Recurrence rates have also been shown to be less after micropulse treatment for CSCR. Multiple studies over the past few years have demonstrated that 577 micropulse laser treatment for CSCR is equivalent or superior to PDT laser, which, up to now, has been the only universally accepted useful treatment for selected cases. Complication rates related to micropulse laser are more favorable in comparison to PDT, where choroidal ischemia can potentially cause loss of vision. Multiple studies have demonstrated the high safety profile of micropulse laser, where no visible structural damage can be shown for many years after treatment, using multiple imaging modalities including OCT and autofluorescence. I have attached links to 3 recent publications for your interest. For any further information please contact the friendly staff at Blink on 02 51040929 or email hello@blink.clinic. hello@blink.clinic www.blink.clinic |